CAS 163451-81-8
:Teriflunomide
Description:
Teriflunomide is an immunomodulatory drug primarily used in the treatment of multiple sclerosis. It is a pyrimidine synthesis inhibitor that works by selectively inhibiting the enzyme dihydroorotate dehydrogenase, which is crucial for the proliferation of activated lymphocytes. This mechanism reduces the number of circulating lymphocytes, thereby modulating the immune response. Teriflunomide is characterized by its relatively long half-life, allowing for once-daily oral dosing. The compound is typically presented as a racemic mixture, with its active form being the levorotatory isomer. It has a moderate solubility in water and is lipophilic, which aids in its absorption and distribution in the body. Common side effects may include liver enzyme elevations, gastrointestinal disturbances, and potential teratogenic effects, necessitating careful monitoring during treatment. Due to its immunosuppressive properties, it is essential for patients to be screened for infections and other contraindications before initiating therapy. Overall, Teriflunomide represents a significant advancement in the management of autoimmune conditions, particularly multiple sclerosis.
Formula:C12H9F3N2O2
InChI:InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
InChI key:InChIKey=UTNUDOFZCWSZMS-YFHOEESVSA-N
SMILES:C(F)(F)(F)C1=CC=C(NC(/C(=C(/C)\O)/C#N)=O)C=C1
Synonyms:- (2Z)-2-(hydroxy{[4-(trifluoromethyl)phenyl]amino}methylidene)-3-oxobutanenitrile
- (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
- (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide
- 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-
- 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
- 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (Z)-
- 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide
- A 1726
- A 77-1726
- A 771726
- A771726
- Active metabolite of leflunomide
- Aubagio
- Femorix
- Flucyamide
- Hmr 1726
- Malononitrilamide
- N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide
- Su 20
- Teriflunomide
- Teriflunomide [INN]
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 17 products.
Leflunomide Related Compound B (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide
CAS:Nitrile function compounds, not elsewhere specified or includedFormula:C12H9F3N2O2Color and Shape:White Off-White PowderMolecular weight:270.06161Teriflunomide
CAS:Nitrile function compounds, nesoiFormula:C12H9F3N2O2Color and Shape:White Crystalline PowderMolecular weight:270.061612-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
CAS:Formula:C12H9F3N2O2Purity:99%Color and Shape:SolidMolecular weight:270.2073Leflunomide EP Impurity B (Leflunomide USP Related Compound B, Teriflunomide)
CAS:Formula:C12H9F3N2O2Color and Shape:White To Off-White SolidMolecular weight:270.21Leflunomide EP Impurity B-d4 (Leflunomide USP Related Compound B-d4, Teriflunomide-d4)
CAS:Formula:C12H5D4F3N2O2Color and Shape:White To Off-White SolidMolecular weight:274.24Teriflunomide
CAS:Formula:C12H9F3N2O2Purity:>98.0%(GC)Color and Shape:White to Almost white powder to crystalMolecular weight:270.21(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide)
CAS:Controlled ProductFormula:C12H9F3N2O2Color and Shape:NeatMolecular weight:270.21Teriflunomide
CAS:<p>Teriflunomide (A 77-1726) is the principal active metabolite of leflunomide, an approved therapy for rheumatoid arthritis and multiple sclerosis.</p>Formula:C12H9F3N2O2Purity:99.54% - 99.95%Color and Shape:SolidMolecular weight:270.21A 77-1726
CAS:<p>Impurity Leflunomide EP Impurity B<br>Applications A77 1726 (Leflunomide EP Impurity B) is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective than injectable interferon beta 1a (Rebif®).<br>References Kirsch, B.M., et al.: Arthritis Research and Therapy, 7, 3, R694, (2005)<br></p>Formula:C12H9F3N2O2Color and Shape:White To Off-WhiteMolecular weight:270.21Teriflunomide
CAS:Controlled Product<p>Inhibitor of dihydroorotate dehydrogenase; anti-inflammatory; immunomodulatory</p>Formula:C12H9F3N2O2Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:270.21 g/molTeriflunomide
CAS:Controlled Product<p>Teriflunomide is a drug that has been clinically proven for the treatment of multiple sclerosis. It is a prodrug that is converted to its active form, teriflunomide-phosphate, in vivo. Teriflunomide inhibits the activity of matrix metalloproteinases by blocking Ca2+ channels and inhibiting Ca2+ influx into the cytosol. This blocks the degradation of extracellular matrix proteins and reduces inflammation, which may lead to long-term efficacy in autoimmune diseases such as multiple sclerosis. Teriflunomide also decreases T-cell proliferation by inhibiting integrin receptors on T cells and monoclonal antibody production.</p>Formula:C12H9F3N2O2Purity:Min. 98 Area-%Molecular weight:270.21 g/mol
![2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA001U44.jpg&w=3840&q=75)
![(2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide (Teriflunomide)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F86%2Fthumb%2FMM0859.02.jpg&w=3840&q=75)
